Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy.

Urologic oncology·2024
Same author

On the Use of Chloral Hydrate in Lethargic Somnolency.

The Homoeopathic physician·2023
Same author

Effects of replacement of barley with oats on milk fatty acid composition in dairy cows fed grass silage-based diets.

Journal of dairy science·2023
Same author

Changes in volatile fatty acid production and microbiome during fermentation of food waste from hospitality sector.

Journal of environmental management·2022
Same author

Evaluating the effects of high-oil rapeseed cake or natural additives on methane emissions and performance of dairy cows.

Journal of dairy science·2021
Same author

Increased Serum Levels of soluble ST2 as a Predictor of Disease Progression in Systemic Sclerosis.

Scandinavian journal of rheumatology·2021

相关实验视频

Updated: May 12, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

在实验性充血性心力衰竭中增强心脏心脏特洛芬-1

M Jougasaki1, I Tachibana, A Luchner

  • 1Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN 55905, USA. jougasaki@mayo.edu

Circulation
|January 5, 2000
PubMed
概括
此摘要是机器生成的。

心脏增生蛋白-1 (CT-1) 在实验性心力衰竭中升高调节,与左心室缩相关. 这表明CT-1在充血性心力衰竭 (CHF) 期间的心脏重塑中起着关键作用.

更多相关视频

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential
07:41

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

相关实验视频

Last Updated: May 12, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential
07:41

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

科学领域:

  • 心血管生物学 心血管生物学
  • 分子心脏病学分子心脏病学
  • 进行心脏重塑.

背景情况:

  • 心脏增生蛋白-1 (CT-1) 是一种强大的增生因子.
  • 使用小鼠胚胎干细胞心脏发生模型发现.

研究的目的:

  • 调查CT-1表达在节奏诱导的充血性心力衰竭 (CHF).
  • 在CHF中确定CT-1和左心室缩之间的关系.

主要方法:

  • 使用了一种犬类模型来进行刺激诱导的实验性CHF.
  • 使用北方斑点分析和免疫组织化学来评估CT-1表达.
  • 与左心室质量指数相关的心室CT-1mRNA.

主要成果:

  • 在正常的心房和心室中检测到CT-1基因表达.
  • 在CHF心脏中,CT-1表达显著增加.
  • 心室CT-1mRNA与左心室质量呈正相关性.
  • 在CHF心脏的心肌细胞中,CT-1免疫活性更强烈.

结论:

  • 前庭和心室都合成CT-1.
  • 在实验性CHF中,心脏CT-1产量增加.
  • 室内CT-1mRNA与左室缩相关,表明在CHF结构重塑中发挥了作用.